Whether hepatitis C virus coinfection might accelerate atherosclerosis in HIV-infected individuals is unclear. We examined the relationship of HIV and hepatitis C virus with carotid artery intima media thickness and the presence of carotid plaques in the Women's Interagency HIV Study. Hepatitis C virus infection was not associated with greater carotid artery intima media thickness after adjustment for demographic and traditional cardiovascular risk factors. Further follow-up is needed to clarify whether HIV/hepatitis C virus coinfection may be associated with a greater risk of carotid plaque.
Whether hepatitis C virus coinfection might accelerate atherosclerosis in HIV-infected individuals is unclear. We examined the relationship of HIV and hepatitis C virus with carotid artery intima media thickness and the presence of carotid plaques in the Women's Interagency HIV Study. Hepatitis C virus infection was not associated with greater carotid artery intima media thickness after adjustment for demographic and traditional cardiovascular risk factors. Further follow-up is needed to clarify whether HIV/hepatitis C virus coinfection may be associated with a greater risk of carotid plaque.
Recent evidence suggests that HIV-infected individuals may be at increased risk for premature atherosclerosis [1, 2] and cardiovascular disease (CVD) [3] [4] [5] . Whether hepatitis C virus (HCV) coinfection might further accelerate atherosclerosis and CVD is unclear. Few studies have examined the association of HIV/HCVcoinfection with CVD [6] ; none have examined the association with atherosclerosis. We determined the relationship between HIV and HCV infection with carotid artery intima media thickness (CIMT) and carotid plaques among participants from the Women's Interagency HIV Study, a multisite prospective cohort of United States women with and at risk for HIV [7, 8] .
CIMT data were collected at one study visit from 2004 to 2005 on 1865 participants enrolled in a carotid ultrasound substudy [9] . HCV antibody (anti-HCV) and confirmatory HCV RNA status was available in 1767 (95%) (1349 anti-HCV negative, 94 anti-HCV positive/HCV RNA negative and 324 anti-HCV positive/HCV RNA positive). Of these, 36 with hepatitis B surface antigenemia and 56 reporting HCV therapy were excluded, yielding a final study population of 1675 (220 HIV/ HCV-coinfected, 53 HCV-monoinfected, 950 HIVmonoinfected, 452 controls).
High-resolution B-mode carotid artery ultrasound was used to image the far wall of the right common carotid artery (CCA), internal carotid artery, and the bifurcation according to a standardized protocol (patents 2005, 2006 ) [9] [10] [11] [12] [13] [14] . The CCA CIMT and the presence of carotid plaques (focal CIMT >1.5 mm in any of the imaged segments) were measured centrally. Image analysis and reproducibility of CIMT measures have been described [9] [10] [11] 13, 14] .
Linear regression models quantified the association of HIV and HCV with the logarithm of CIMT as a continuous outcome. The ratio of the median CIMT values of two groups with different exposures were obtained by exponentiation of appropriate model coefficients and used as the measure of association between exposure and outcome [15] . Logistic regression models quantified the association of HIV and HCV with the presence of at least one carotid plaque as a binary outcome. Multiple regression models adjusted for demographic and traditional cardiovascular risk factors.
Hepatitis C virus-infected women were older (medians of 48 and 49 years in HIV/HCV-coinfected and HCVmonoinfected, respectively, versus 39 and 36 years in HIV-monoinfected and controls, respectively); more likely to report a longer median duration of smoking (26 and 27 years versus 5 and 7 years), to have diabetes mellitus (23% and 26% versus 14%-and 6%), and to have a higher median systolic and diastolic blood pressure (123/76 and 123/74 mmHg versus 115/70 and 116/ 69 mm/Hg), but lower median LDL-cholesterol level (78 and 81 mg/dl versus 104 and 99 mg/dl). Among HIVinfected women, those with HCV-coinfection had a lower median CD4 cell count (367 versus 442 cells/ml) and higher median HIV RNA (2.92 versus 2.32 log 10copies/ml), and were less likely to be on highly active antiretroviral therapy (58% versus 67%).
The median CIMT was similar between HIV/HCVcoinfected and HCV-monoinfected women; both HCV-infected groups had higher CIMT than HIVmonoinfected and those with neither infection ( Table 1) . The prevalence of carotid plaques was higher in HIV/ HCV-coinfected than HCV-monoinfected women; both were higher than the prevalence in HIV-monoinfected and control women.
After adjustment, HCV infection was no longer associated with greater CIMT, regardless of HIV status compared to controls. Additionally, the 4.28-fold and the 2.40-fold higher odds of carotid plaques among HIV/HCV-coinfected and HCV-monoinfected women, respectively, was attenuated and not statistically significant after adjustment.
Our findings of a lack of an association between HCV infection and greater CIMT are contrary to prior studies [16] [17] [18] [19] . On the contrary, HIV/HCV coinfection may be associated with higher odds of carotid plaques than those with neither infection. There are several potential reasons for the differences between our study and other studies.
First, our study is the first to examine the association of HIV/HCV coinfection with CIMT and includes a large sample of individuals with confirmed HCV infection. Prior CIMT studies have been in HCV-monoinfected individuals and have mainly used large population-based health-screening examinations to identify anti-HCVpositive cases and controls. In our study, women with and without HIV infection had similar high-risk behaviors for HIV and HCV transmission.
Second, our study controlled for smoking duration; other studies controlled for smoking history. Smoking duration has been associated with CIMT [20] . It is noteworthy that HCV-infected women in our study, on average, reported smoking for 20 more years than HCV-uninfected women (beyond the difference in the median age for the groups). Diabetes determined using fasting glucose parameters was also highly prevalent in our HCV cases. Previous studies indicate that traditional cardiovascular risk factors (rather than HIV infection itself) account for CIMT differences between HIV-infected and HIV-uninfected individuals [10, 11] . These factors may also account for the CIMT differences between HCV-infected and HCV-uninfected individuals, although the attenuation in the association between HCV infection and CIMToccurred mainly after adjustment for age and race.
Interestingly, the association of HIV/HCV coinfection and HIV monoinfection with carotid plaques was in a positive direction, whereas the association with CCA CIMT was in a negative direction. A study comparing HCV-monoinfected with uninfected individuals found that HCV core protein was strongly associated with carotid plaques and weakly associated with CCA CIMT [18] . Similar to our study, carotid plaque was defined as the presence of focally increased CIMT in any of the CCA, internal carotid artery or bifurcation. These data could suggest a differential affect of HCV infection on the different segments of the carotid artery.
A limitation of our study is its cross-sectional design, which included few HCV-monoinfected cases and so the association of HCV monoinfection with CIMT and carotid plaques should be interpreted with caution. Our findings may also represent confounding by other factors associated with HCV infection, such as injection drug use. Nonetheless, our study included large numbers of participants, used a robust definition of HCV infection, and had a rich database of biologic, demographic, and behavioral characteristics. In summary, contrary to prior studies, we did not find an association of HCV infection with greater CIMT after adjustment for demographic and traditional cardiovascular risk factors. HIV/HCV coinfection may be associated with a greater risk of carotid plaques; further follow-up over time should clarify this question. Additionally, whether HCV infection might differentially affect the development and progression of subclinical atherosclerosis in the different segments of the carotid artery should be evaluated.
In 2007, the WHO recommended a maximum stavudine dose of 30 mg. We compared virologic suppression among patients weighing more than 60 kg and receiving stavudine 30 mg (n U 110) versus 40 mg (n U 508) in community HIV clinics in South Africa, before and after guidelines changed. At 6 months, HIV RNA less than 400 copies/ml was achieved in 79% and 81% receiving 30 and 40 mg stavudine, respectively (x 2 , P U 0.6). In regression modeling, including baseline HIV RNA and nonnucleoside reverse transcriptase inhibitor agent, stavudine dose remained unassociated with suppression.
Background
Combination antiretroviral therapy (cART) including stavudine, lamivudine, and nevirapine is the most widely used regimen in Africa [1] . This regimen achieves good virologic response but troubling long-term complications (usually starting after >6 months cART) [2] [3] [4] [5] . In response to the high rates of adverse events, in 2007, the World Health Organization (WHO) recommended using stavudine 30 mg twice daily for all adults, replacing the 40 mg dose for adults over 60 kg [6] . This was based on results of short-term dose ranging studies [7] [8] [9] and retrospective cohort analyses. A recent meta-analysis [10] also suggested the similar performance of 30 mg and 40 mg stavudine. However, evaluation of outcomes of ART naïve patients weighing more than 60 kg initiated on stavudine 30 mg is lacking from Africa. In our community-based ART programmes, we changed from use of 40 mg to 30 mg for individuals weighing more than 60 kg in mid-2007. We compared virologic suppression and CD4 cell response at 6 months among individuals weighing more than 60 kg who received a stable dose of either 30 or 40 mg of stavudine.
Methods
Patients in this study were enrolled in community HIV care programmes, followed 6 months from cART initiation, and fulfilled the following criteria: initiated cART including stavudine of either 40 mg or 30 mg between 1 January 2006 and 1 January 2008; received a stable dose of stavudine; weighed more than 60 kg at cART initiation and during observation; received a nonnucleoside reverse transcriptase inhibitor (NNRTI); were cART naïve and had a known date of cART initiation, had at least 150 days follow-up after cART initiation, and were at least 18 years old. Baseline factors were compared between individuals receiving 30 mg and 40 mg stavudine using chi-square and Wilcoxon rank sum tests, as appropriate. HIV RNA response was based on the lowest HIV RNA obtained within 6 months of cART initiation. If no HIV RNA test result was available, the subject was considered to have HIV RNA more than 400 copies/ml to avoid excluding individuals without HIV RNA results because of discontinuation due to intolerance. We assessed the impact of classifying these individuals as treatment failures in a sensitivity analysis. The chi-square test was used to compare the proportion achieving HIV RNA less than 400 copies/ml or less than 50 copies/ml by stavudine group. Logistic regression was used to assess associations between covariates and HIV RNA suppression and to adjust for confounding; a multivariate model was built by including covariates with P 0.1. CD4 cell change from cART initiation to 6 months was compared, by stavudine group, using the Wilcoxon rank sum test. Ethical approval was obtained from the University of KwaZulu-Natal and the London School of Hygiene and Tropical Medicine.
Results
Six hundred and ninety-one patients were evaluated for analysis: 618 were included, 73 were excluded because of a change in stavudine dose or because stavudine dose was not recorded at a visit. Sex, age, and HIV RNA less than 400 copies/ml at 6 months were similar between included and excluded patients. Of the included cART naïve individuals (all weighed more than 60 kg at baseline and initiated cART between January 2006 and January 2008 at 51 community ART clinic sites), 110 received 30 mg and 508 received 40 mg stavudine. The two stavudine dose groups were different with respect to WHO stage, proportion receiving efavirenz, weight, and median log 10 HIV RNA and CD4 cell count at cART initiation (Table 1) . Nine (8.1%) in the 30 mg group and 46 (9.1%) in the 40 mg group had no HIV RNA measurement during the observation period and were counted as treatment failures.
We observed similar virologic suppression using less than 400 copies/ml and less than 50 copies/ml at 6 months by stavudine group: suppression to less than 400 copies/ml for 30 mg was 87/110 [79%, 95% confidence interval (CI) ¼ 71-87%] and for 40 mg was 413/508 (81%, 95% CI ¼ 78-85%) (P ¼ 0.6); less than 50 copies/ml for 30 mg was 66/110, (60%, 95% CI ¼ 51-69%) and for 40 mg was 297/508, (58%, 95% CI ¼ 54-63%) (P ¼ 0.8).
Completing sensitivity analysis excluding individuals without follow-up HIV RNA testing, we found 86% (95% CI ¼ 0.79-0.93) and 89% (95% CI ¼ 0.86-0.92) were suppressed with stavudine 30 mg or 40 mg groups, respectively (P ¼ 0.3). Using logistic regression we found no association between HIV RNA suppression and sex, weight, or WHO stage at cART initiation (Table 1) . On univariate analysis, log 10 HIV RNA at cART initiation, NNRTI agent, and weight all had P values less than 0.1 for odds of achieving an HIV RNA less than 400 copies/ml. On multivariate analysis adjusting for NNRTI agent, weight, and HIV RNA at cART initiation, stavudine dose remained unassociated with suppression (Table 1 ). CD4 cell change from cART initiation to 6 months on cART increased with a median of 126 cells/mm 3 (interquartile range ¼ 87-206) for the 30 mg group and 110 cells/mm 3 (interquartile range ¼ 50-170) for the 40 mg group (P ¼ 0.02).
Discussion
In an African operational cohort, we found that HIV RNA suppression at 6 months was similar between the two-stavudine doses in patients weighing more than 60 kg. Although the recipients were not randomized to dose, the dose decisions were made based on a change in guidelines and not as a result of individualization of patient management, reducing the chance of selection bias. However, our two stavudine groups did differ in some characteristics: the group receiving 30 mg of stavudine had a lower CD4 cell count and higher WHO clinical stage at HAART initiation and was more likely to receive nevirapine. These are factors sometimes associated with poorer HAART response [11] [12] [13] , yet our outcomes were similar. On the basis of virologic outcomes at 6 months, our results provide additional support for the WHO recommendations for use of 30 mg stavudine among individuals weighing more than 60 kg. Long-term (>18 months) evaluation of side effects is essential to compare tolerance of stavudine 30 mg versus 40 mg.
19 months. Upon returning to care, 33 out of 74 patients (44.6%) had CD4 cell counts less than 200/mm 3 and/or AIDS. Patients who returned to care after LTFU were five times more likely to die than patients who attended clinic regularly.
The increasingly widespread use of combination antiretroviral therapy (cART) since 1996 has substantially improved the prognosis of HIV-infected patients who have access to these drugs [1] [2] [3] [4] . Despite this improvement in HIV treatment, some patients discontinue their clinical follow-up [5, 6] . Several recent studies have analyzed the factors associated with loss to follow-up (LTFU) [7] [8] [9] [10] [11] , but, to our knowledge, no study has assessed outcomes in patients who are lost to follow-up. The aims of this study were to evaluate the characteristics of patients who returned to care after LTFU and to estimate their risk of death compared with patients who attended clinic regularly.
In a recent study, we estimated the incidence of and risk factors for LTFU in 1007 HIV-infected patients in five clinical centres in the Nord Pas-de-Calais region of France, from January 1997 to December 2006 [11] .
Overall, 135 patients (13.4%) were lost to follow-up during the study period [11] and the incidence of LTFU was 3.5 per 100 person-years. Patients were considered to be lost to follow-up if: they did not show upto their clinic for at least 12 months; they were not known to be under the care of a physician or at any other hospital during this period; and they were not known to have died within 12 months of their last visit [11] .
In the current study, we first determined the proportion of patients who returned to care after LTFU. Next, we assessed the risk of death associated with returning to care after varying durations of LTFU, compared with regular clinic attendance, by determining the time to death since first presentation to care. We assessed this association using the Kaplan-Meier method with the Log rank test.
Using a multivariate Cox [12] proportional hazard model, we adjusted the risk of death by duration of LTFU, CD4 cell count and the presence or absence of AIDS-defining events at enrollment. When we adjusted for CD4 cell count and AIDSdefining events at enrollment, patients who returned to care after LTFU were 5.14 times more likely to die than patients who attended clinic regularly (95% confidence interval ¼ 2.11-12.54) (Fig. 1) . The causes of death among patients who returned to care after LTFU were: multiple opportunistic infections (pneumocystosis, esophageal candidiasis, CMV infection) in four patients, cerebral toxoplasmosis in one patient and mandibular malignancy in one patient.
The incidence of LTFU in our study was comparable to that reported by Mocroft et al. [10] in the Eurosida cohort. Few studies have estimated the proportion of HIV-infected patients who return to care after LTFU. In the study by Mocroft et al. [10] , only 27.1% of patients who were LTFU for more than 1 year returned to care (743/2743 patients), compared with 54.8% (74/135) in our study [10] . We should be cautious when comparing these study results. This discrepancy may be explained by the different settings in which these studies were conducted: Eurosida comprised 93 centres across Europe as well as HIV centres in Eastern Europe and Argentina [10] , whereas our was conducted in a single region of France. In addition, the Eurosida cohort contained precARTera patients, whereas ours did not. Finally, since 2002, trained technicians contact all patients who are lost to follow-up in the Nord Pas-de-Calais region to persuade them to return to care, but no such system existed for the Eurosida cohort.
As in other studies [8, 13] , most of the patients who were lost to follow-up were asymptomatic at the time of LTFU: 47 patients (63.5%) had CD4 cell counts more than 350/mm 3 and no history of AIDS-defining events.
In contrast, upon return to care, 33 patients (44.6%) had CD4 cell counts less than 200/mm 3 and/or AIDSdefining illness. Similar to patients who present to care very late, these patients are more likely to have one or more AIDS-defining illnesses, to be hospitalized as a result of an AIDS-defining event, and to die [14] . Patients who returned to care after LTFU in our study were five times more likely to die than patients who attended clinic regularly. In another study on HIV-infected patients in the 2006 French hospital database, the risk of death in patients with delayed accessed to care (CD4 cell count less than 200/mm 3 and/or AIDS at enrollment) was 13 times higher 6 months after enrollment, and five times higher 12 months after enrollment [15] . LTFU may also increase the risk of HIV transmission, as patients who interrupt cART cannot benefit from the favorable effect of antiretroviral drugs on infectiousness [16] . Increased efforts are needed to reduce LTFU and to encourage those patients who no longer attend clinic to return to care.
